Algo version: 0.98b
Lees Pharmaceutical is listed at the HKSE Exchange
Lees Pharmaceutical [0950.HK]
HKSE Sector: Healthcare Industry:Drug Manufacturers Specialty Generic

Is Lees Pharmaceutical stock a buy?

What Is The Conclusion?

Right now our advanced algorithms say:

Do the analyst corps agree?

Interesting Questions and Easy Answers!

Yes, Lees Pharmaceutical pays dividends. Last time was Thursday 3rd of October 2024 where the investors holding the stock on Thursday 12th of September 2024 were paid HKD0.02 per share. Over the last 35 times between 2008 and 2024, Lees Pharmaceutical has paid HKD1.051 with an average of HKD0.03 per share.

Sorry, we do not have any analyst data for this ticker

We cannot find data for Lees Pharmaceutical 10 years ago, but if you had invested on Friday 22nd of November 2019 when the price was HKD4.14, you would have made a loss of HKD-2.91 per share or -70.29%

No, the average daily trading liquidity for Lees Pharmaceutical is HKD94 300 thousand. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.

Lees Pharmaceutical has little of the business financed by loans. This puts the company at lower risk in periods of high inflation where borrowing costs usually go up. With a normal cash flow to debt ratio of 0.47, the company's ability to pay off the debt is normal. The company has a very low net profit margin of 1.08%, which is challenging.

We have calculated the inflation risk for Lees Pharmaceutical to be low [0.35 of 1]

US inflation for August 2024 was 0.19%. Over the last 12 months, the US inflation is 2.59%. The 10-year treasury yield that indicates the future interest level is currently 4.41 and is up 0.05 over the last 30 days.